The Beta 2 Adrenergic Receptor pipeline drugs market research report outlays comprehensive information on the Beta 2 Adrenergic Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Beta 2 Adrenergic Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Ophthalmology, Immunology, and Cardiovascular which include the indications Asthma, Chronic Obstructive Pulmonary Disease (COPD), Ocular Hypertension, Open-Angle Glaucoma, Anaphylaxis, Allergies, Congestive Heart Failure (Heart Failure), and Left Ventricular Dysfunction. It also reviews key players involved in Beta 2 Adrenergic Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Beta 2 Adrenergic Receptor pipeline targets constitutes close to 67 molecules. Out of which, approximately 62 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 2, 15, 13, 8, 4, 11, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 1 molecule.
Beta 2 Adrenergic Receptor overview
The beta-2 adrenergic receptor (β2AR) is a G protein-coupled receptor (GPCR) that is found in many tissues throughout the body, including the lungs, heart, and liver. When activated by its ligand, epinephrine (adrenaline), the β2AR triggers a signaling cascade that leads to a variety of physiological effects, including bronchodilation, increased heart rate, and glycogenolysis.
For a complete picture of Beta 2 Adrenergic Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
